BioTrace Medical Inc. announced in December the first commercial use of the company’s Tempo Temporary Pacing Lead since U.S. Food and Drug Administration (FDA) 510(k) clearance in October 2016.

Acist Medical Systems Inc. announced that enrollment is complete for its Fractional Flow Reserve (FFR) Study – Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve measurement. The study, which began in November 2015, included 240 patients at 12 sites across the United States. Final results are expected to be released in mid-2017.

According to a recent study by the Harvey L. Neiman Health Policy Institute, the last two decades have seen a substantial decline in new enteral access procedures in the Medicare population. The study, published online in November in the Journal of Vascular and Interventional Radiology (JVIR), also found that maintenance services have increased, with radiologists and emergency physicians surpassing gastroenterologists and surgeons as the leading providers of those procedures.

For patients with atrial fibrillation, the most common form of heart arrhythmia, a main goal of treatment is stroke prevention. As a result, most Afib patients are prescribed a blood thinner such as warfarin, also known by the brand name Coumadin, to combat the potential for blood clots that could lead to stroke. But warfarin is tough to manage, and some patients have trouble adhering to any medication. A new research letter published in JAMA Cardiology finds Afib patients are even more likely to discontinue warfarin therapy if they’ve had a recent procedure done to address their arrhythmia.